Skip to main content

Hospital Acquired Pneumonia- Definition, Predisposing Factors, Clinical Features and Management!

 HOSPITAL ACQUIRED PNEUMONIA

Definition:

"HAP refers to a new episode of pneumonia occurring at least 2 days after the administration to hospital. It is the most common Hospital Acquired Infection (HAI) and leading cause of HAI-associated death".



Predisposing factors:

  1. Aspiration of nasopharyngeal secretion
  2. Bacteria introduced into the lower GIT.
  3. Bacteriaemia
  4. Old age


Mode of Spread:

  •  Droplet infection


Infecting agent:

Bacteria: S.pneumonia , S.aureus , H.influenza

Virus: Adenovirus, Corona virus, Herpes Simplex


Clinical Features:

  • Purulent sputum
  • New radiological infiltrates
  • Temperature > 38 degree Celsius
  • Leukocytosis


Investigations:

  1. Chest Pain: to confirm the diagnosis and exclude complication.
  2. Pulse Oximetry: to monitor response to oxygen therapy, if SaO2 < 93% features of sever pneumonia, identify ventilatory failure or acidosis.
  3. Cell count: ESR, Neutrophil leukocytosis
  4. Microbiological studies: for severe CAP and those that do not respond to initial therapy (Gram stain, sputum culture, blood culture)
  5. Renal Function test: Urea and Electrolytes
  6. Liver Function test: Elevated C-Reactive protein
  7. Complete Blood Count (CBC)
  8. Chest X-Ray

Management:

The goal for management involves:
  • Oxygen therapy
  • Fluid balance
  • Antibiotic therapy
  • In severe illness--Nutrition support


1. Oxygen Therapy:
  • Oxygen should be administered to all the patients with tachypnea, hypoxemia, hypotension with the aim of maintaining SaO2 at >92%.
  • Indicated for: Referral to Intensive Therapy Unit (ITU) including.
  1. Persistent hypoxia SaO2 <90% despite high concentration of O2.
  2. Severe acidosis
  3. Circulatory shock
  4. Reduced conscious level.

2. IV Fluids:
  • should be considered in patients with severe illness, older patients, those who are vomiting. Oral fluid intake is encouraged.

3.Antibiotics:

  • Patients who have not received antibiotics previously can be treated with Co-Amoxiclav.
  • If patients have received course of recent antibiotic, then Piperacillin/Tazobactam/Cephalosporin
  • If patients have late onset of HAP, choice of antibiotics must cover Gram Negative S.aureus and anaerobes.
  • Anti-pseudomonal cover is provided by Carbapenem or 3rd Generation Cephalosporin and Aminoglycosides
  • MRSA cover provided by glycopeptides such as Vancomycin.



Labels:

Comments

Post a Comment

Popular posts from this blog

Diabetes Mellitus: Types!

TYPES OF DIABETES MELLITUS 1. TYPE1 DM Type 1 DM is usually diagnosed before age 30 years, but it can develop at any age. T1DM is an autoimmune disease in which insulin producing B-cells are destroyed. The presence of Human Leucocyte Antigens (HLAs ) is associated with the development of T1DM. In addition, these individuals often develop Islet cell antibodies , Insulin Autoantibodies or Glutamic Acid decarboxylase autoantibodies . At the time of development of diagnosis of T1DM, it is usually believed that most of the patients have 80-90%loss of beta cells. The remaining beta cells function at the diagnosis creates a " HONEYMOON PERIOD" during which the blood glucose levels are easier to control, and smaller amounts of insulin are required. after this, the remaining beta cells function is completely lost, and the patients become completely deficient of insulin and hence require exogenous insulin.  2. TYPE1.5 DM:  Also referred as Latent autoimmune diabetes in Adults (LAD)
Post a Comment
Read more

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

  PHARMACOTHERAPY:  Medications classifications include:  Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors  Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions.  Clinical Use: FPG concentrations have been decreased by 40-50mg/dL and A1c level
Post a Comment
Read more

GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)!

MANAGEMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE  "GERD refers to the endoscopically determined esophagitis or endoscopy-negative reflux disease" . "GERD is the term used to describe any symptomatic clinical condition or histopathological alteration resulting from episodes of reflux of acid, pepsin and occasionally, bile into the esophagus from the stomach". Patients with uninvestigated "reflux-like" symptoms should be managed as patients with uninvestigated dyspepsia. There is currently no evidence that H.pylori should be investigated in patients with GERD. Symptoms: Heartburn is the characteristic symptom of GERD. Acid regurgitation Dysphagia Belching Upper abdominal discomfort Bloating and postprandial fullness Chest pain Hoarseness Cough Complications include: Esophageal ulceration Formation of specialized columnar-lined esophagus at the gastro-esophageal junction known as Barretts Esophagus . Mechanism of Acid Reflux: The mechanism of acid reflux is mu
Post a Comment
Read more